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Abstract 
The serine proteinase inhibitor alpha-1 antitrypsin (AAT) is produced principally by 
the liver from where it is secreted into the circulation and provides an antiprotease protective 
screen throughout the body. Mutations leading to deficiency in AAT are associated with liver 
and lung disease. The most notable is the Z mutation, which encodes a misfolded variant of 
the AAT protein in which the glutamic acid at position 342 is replaced by a lysine. ZAAT is 
not secreted effectively and accumulates intracellularly in the endoplasmic reticulum (ER) of 
hepatocytes and other AAT-producing cells. The ER has evolved a number of elegant 
mechanisms to manage the accumulation of incorrectly folded proteins; ZAAT interferes with 
this function and promotes ER stress responses and inflammation. Until recently it was 
thought that gain of function was the major cause of the liver disease whilst the lung disease 
was entirely due to loss of anti-protease protection in the lung. This belief is now being 
challenged with the discovery that ER stress is also activated in bronchial epithelial cells and 
inflammatory cells normally resident in the lung in ZAAT deficient individuals. Here we 
describe the gain of function effects of ZAAT. In particular we highlight the signalling 
pathways that are activated during ER stress in response to accumulation of ZAAT and how 
these events are linked to inflammation and may contribute to disease pathogenesis.  
 
 
Keywords: alpha-1 antitrypsin deficiency, apoptosis, endoplasmic reticulum stress, 
inflammation, NF-κB, unfolded protein response 
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Introduction 
Alpha-1 antitrypsin (AAT) deficiency is a hereditary disorder which predominantly 
affects the lungs and to a lesser extent, the liver. AAT is synthesized primarily in the liver [1] 
but is also expressed by a variety of other cells including monocytes, neutrophils, alveolar 
macrophages, bronchial and intestinal epithelial cells[2-7]. AAT is the archetypal member of 
the serpin superfamily, whose members regulate the activity of serine proteases most 
notably neutrophil elastase (NE)[8]. If unchecked, NE and other serine proteases can 
degrade the lung matrix causing structural damage and pathologically impairing host 
defence. The most clinically significant mutation associated with AAT deficiency is the Z 
mutation, which causes the abnormal Z protein to misfold and polymerise within hepatocytes 
of the liver [9] and other AAT–producing cells. This intracellular retention leads to a serum 
deficiency of AAT, rendering the lungs vulnerable to proteolytic attack and the liver prone to 
cirrhosis due to the abnormal aggregation of AAT. As our understanding of ZAAT deficiency 
has increased over the last few years it has emerged that toxic effects associated with 
intracellular accumulation of ZAAT in the endoplasmic reticulum (ER) and the acquisition of 
new proinflammatory properties by misfolded ZAAT also contribute to the pathognesis of this 
disorder. Here we discuss the gain of function effects of Z alpha-1 antitrypsin. 
 
Z AAT CAN ACT AS A CHEMOATTRACTANT 
The observation by Lomas et al. that ZAAT can form polymers within hepatocytes9 
initially raised the possibility of polymers existing in the lung and contributing to the 
pathogenesis of emphysema. Although the majority of AAT is derived from the liver and 
enters the lung from the circulation by passive diffusion, macrophages and bronchial and 
alveolar epithelial cells also secrete AAT locally. Regardless of origin, ZAAT has the 
propensity to form polymers. The first identification of AAT polymers in lung lavage [10] and 
lung tissue [11] of ZZ individuals led to functional studies of AAT polymers. Initially, polymers 
of wild type MAAT were shown to be chemotactic for neutrophils, inducing neutrophil shape 
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change, enzyme release and adhesion [12]. In contrast, monomers of AAT had little effect 
on the migration of neutrophils in vivo or in vitro.  
As the Z form of AAT is more intrinsically polymerogenic than the M form, the 
acquired characteristics of AAT polymers could help drive the development of emphysema in 
ZZ individuals. Indeed, the instillation of AAT polymers into mouse lung caused a neutrophil 
influx [11]. More importantly, work from this group and others demonstrated that locally 
produced ZAAT actually polymerises in the lung and can act as a potent neutrophil 
chemoattractant. ZAAT polymers have also been found co-localised with neutrophils in the 
alveolar wall of AAT deficiency individuals with emphysema [11, 13]. This concept of 
polymer-induced neutrophil influx is supported by clinical evidence of increased neutrophils 
in lung lavage from ZZ individuals [14]. It remains to be demonstrated whether ZAAT forms 
polymers in vivo in airway epithelial cells. 
 
Protein Folding in the ER and ER Stress  
AAT deficiency is characterised by aberrant folding of AAT protein and therefore 
belongs to a class of genetic conditions collectively termed conformational disorders [15], 
diseases caused by mutations altering the folding pathway or the final conformation of a 
protein. Other conformational disorders include cystic fibrosis, Parkinson’s disease and 
Alzheimer’s disease, and are all associated with intracellular accumulation of unfolded or 
misfolded rogue proteins. AAT deficiency can also be classified as an ER storage disease as 
it involves a mutation that affects the AAT polypeptide, resulting in retention of the abnormal 
AAT cargo in the ER [16]. This accumulation of aberrantly folded Z protein within the ER 
lumen has the potential to cause the phenomenon of ER stress – the three classical features 
of ER stress are the unfolded protein response, the ER overload response and apoptosis. 
Because of the importance of accurate protein folding sophisticated cellular 
mechanisms have evolved to ensure correct protein folding and efficient disposal of 
irreversibly misfolded proteins. These mechanisms are designed to ensure that only properly 
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folded proteins can exit from the ER. Proteins enter the ER in an unfolded state via a 
heterotrimeric Sec61p channel. Various chaperones residing in the ER facilitate folding of 
these nascent polypeptides via modifications such as disulphide bind formation and N-linked 
glycosylation. Faulty polypeptides generated via this process are disposed of [17]. 
Polypeptides undergo quality control in the ER and are confined there by the lectin-
type chaperones calnexin and calreticulin which assist in their folding until it has been 
properly completed. Glucose-responsive protein 78 (BIP/Grp78) can bind to exposed 
hydrophobic surfaces whilst oxidoreductases such as Glucose-responsive protein 58 
(Grp58/ERp57) bind free thiol groups and catalyse the formation of intra- and inter-molecular 
disulfide bonds between paired cysteine residues. Protein disulfide isomerase, a redox-
driven chaperone, is also involved in ER quality control. Immature deglucosylated 
glycoproteins are recognised by UDP glucose-glycoprotein glucosyltransferase (UGT1) an 
ER folding sensor, which retains them in the ER for reglucosylation and further calnexin-
calreticulin assisted folding. Once correctly folded, proteins are transported to the Golgi 
apparatus for membrane insertion or secretion [18]. 
ER homeostasis is essential for normal cell function and survival. Environmental 
perturbations such as disturbances in calcium storage compromise the ER protein folding 
capacity, resulting in the accumulation of unfolded or misfolded protein within the ER. Any 
imbalance between the ER protein folding load and the ability to process the load causes ER 
stress, with potentially pathological consequences. ER stress can also be induced by a 
range of pathophysiological conditions, including ischaemia, diabetes, viral infection, and 
mutations which impair client protein folding [19]. Therefore, to maintain homeostasis, the 
ER has evolved mechanisms to sense stress and transduce signals to the cytoplasm and 
the nucleus, governing whether the outcome is survival or death. This protective system 
includes the translational attenuation of protein synthesis [20], transcriptional induction of 
unfolded protein response (UPR) target genes [21], and ER-associated degradation 
(ERAD)[22]. Collectively this tripartite management system is called the unfolded protein 
response (Figure 1). 
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UPR 
(i) Translational Attenuation - PERK Pathway. When mammalian cells are subjected to ER 
stress, the first and immediate response is translational attenuation in order to reduce the 
load of host protein synthesis in the ER and prevent the further accumulation of unfolded 
proteins [23]. This is orchestrated by the type I ER transmembrane protein Protein kinase-
like ER kinase (PERK), which represses global protein biosynthesis through the 
phosphorylation of translation initiation factor 2 (eIF2) on its alpha subunit (eIF2α). The 
lumenal domain of PERK is sequestered by Grp78 in unstressed cells at the ER membrane 
and its cytoplasmic domain is activated upon the release of Grp78 following ER stress. 
PERK then oligomerises and auto-phosphorylates to become active, and can trans-
phosphorylate the translation initiation factor eIF2α [24] and the basic leucine zipper (bZIP) 
transcription factor NF-E2-related factor 2 (Nrf2) [25].  
The phosphorylation of eIF2α at serine 51 in response to various stresses blocks the 
initiation of global translation in the cell, but simultaneously upregulates a subset of stress-
responsive genes; eIF2α phosphorylation paradoxically promotes the translation of 
Activating transcription factor (ATF) 4 mRNA, another bZIP transcription factor [26]. ATF4 
regulates the expression of genes essential for amino acid import, glutathione biosynthesis, 
resistance to oxidative stress and restoring ER homeostasis [26]. Downstream targets of 
ATF4 include C/EBP homologous protein (CHOP), Growth Arrest and DNA Damage-
Inducible Protein (GADD34), and ATF3 [27, 28]. A key role for ATF4 in cell survival is 
underlined by the high expression levels found in malignant tissue from several types of 
cancer, including brain, breast, cervical and skin cancers, facilitating tumour growth and 
survival [29]. In addition, the downstream target ATF3 contributes to the expression of the 
pro-apoptotic protein CHOP and the phosphatase GADD34 [28], adding another layer of 
complexity and providing a further example of the highly coordinated and integrated 
approach of the cell to ER stress.  
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During ER stress PERK also induces phosphorylation of the transcription factor Nrf2, 
allowing it to dissociate from an inactive complex in the cytoplasm, and facilitating its nuclear 
translocation. Nrf2 transactivation appears to be independent yet parallel to eIF2α 
phosphorylation, and raises the possibility of two or more divergent pathways downstream of 
PERK. In the nucleus Nrf2 binds to antioxidant response elements (ARE), promoting a 
transcriptional programme of pro-survival genes, similar to ATF4 [30]. Besides genes 
required for coping with oxidative stress and maintaining redox homeostasis, other Nrf2-
regulated genes include those involved in immune signalling, protein trafficking, protein 
degradation and the chaperone system [31]. Disruption of Nrf2 in mice impairs the induction 
of cytoprotective genes and enhances cigarette-induced emphysema caused by oxidative 
damage, inflammation and apoptosis [32]. Defective Nrf2 signalling has also been identified 
in the lungs of patients with chronic obstructive pulmonary disease, indicating that host 
antioxidant defences are attenuated [33]. It is known that reactive oxygen species are 
generated by misfolded proteins in the ER, and antioxidants have been shown to reduce 
UPR activation, oxidative stress and apoptosis [34].  
 
(ii)Transcriptional Induction of UPR - ATF6 Pathway. ATF6 is an ER-resident type II 
transmembrane protein with an N-terminal cytoplasmic region containing bZIP and DNA 
transactivation domains, and a C-terminal lumenal region that senses ER stress [35, 36]. 
During ER stress, ATF6 translocates to the Golgi complex after the dissociation of Grp78, 
which masks Golgi localisation signals on the luminal region of ATF6. In the Golgi ATF6 
undergoes sequential proteolytic cleavage by site-1 and site-2 proteases and the bZIP-
containing N-terminal moiety becomes a soluble transcription factor that translocates to the 
nucleus. ATF6 binds to the ATF/CRE element [37] and to the ER stress response elements 
(ERSE) I and II [38, 39]. Binding of ATF6 to ERSE-I requires another transcription factor, 
Nuclear transcription factor Y (NF-Y) [40]. Some of the target genes regulated by ATF6 
include GRP78, X-box binding protein-1 (XBP-1), CHOP/GADD153, and the membrane 
protein Herp [41].  
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(iii) IRE1 Pathway. The ER transmembrane protein inositol requiring kinase 1 (IRE1) 
regulates chaperone induction, ERAD, and expansion of the ER in response to ER stress 
[42]. This pathway is highly conserved in evolution and is present in all eukaryotes. 
Mammals have two copies of IRE1, IRE1α and IRE1β. IRE1α is ubiquitously expressed, 
while the expression of IRE1β is limited to the gut [43, 44]. IRE1 is an endoribonuclease, and 
after dissociation of Grp78 from its ER lumenal domain, IRE1 oligomerises and activates its 
RNase domain [45]. The target of IRE1 is the bZIP transcription factor XBP-1. The stress-
induced spliced version of XBP-1 travels into the nucleus and can bind to both ERSE and 
UPRE, activating the transcription of ER chaperone genes, ER quality control genes and 
folding enzymes [46]. Degradation of unspliced XBP-1 by the proteosome is vital for efficient 
activation of the UPR as it occupies UPRE sites and forms less potent dimers with spliced 
XBP-1 [47].  
Interestingly, cleavage of ATF6 occurs prior to spliced XBP-1 production, which 
suggests the two UPR transcription pathways are biphasic [48]. ATF6 activation is relatively 
rapid as it involves proteolysis of a pre-existing protein, whereas activation of XBP-1 requires 
mRNA transcription, splicing and translation. Furthermore, ATF6 preferentially binds to the 
ERSE sequence in the presence of NF-Y, while XBP-1 can bind to both ERSE and unfolded 
protein response elements (UPRE) sequences. This would suggest that mammalian cells 
activate ATF6 to induce transcription via ERSE immediately upon ER stress, and then 
activate XBP-1 to induce UPRE-mediated as well as ERSE-mediated transcription. The 
XBP-1 promoter contains a mammalian UPRE site, suggesting a positive feedback 
mechanism for gene transcription. This may allow for sustained UPR activation in cells 
undergoing chronic ER stress [46].  
 
UPR and Inflammation 
ER stress is intrinsically linked to the generation and accumulation of reactive oxygen 
species (ROS). The efficient folding of newly synthesised proteins into the correct 
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conformations in the ER is an energy-consuming process, and oxidising conditions are 
essential for the formation of intramolecular and intermolecular disulphide bonds [49]. It 
stands to reason that any increase in the protein-folding load in the ER can lead to the 
accumulation of ROS, with deleterious inflammatory consequences [50]. The evolutionarily 
conserved PERK pathway of the UPR, with an antioxidant transcriptional programme 
mediated by ATF4 and Nrf2, is testament to the harmful effects of ROS accumulation.  
In addition to its role in preserving ER homeostasis and promoting cell survival, it is clear 
that ER stress-induced UPR activation influences the expression of inflammatory cytokines. 
The key UPR sensor IRE1 appears to coordinate ER stress-signalling with inflammatory 
response signalling. IRE1 has been to shown to bind the adaptor protein tumour necrosis 
factor-α-receptor-associated factor 2 (TRAF2) [51]. The IRE1-TRAF2 complex can recruit 
inhibitor of nuclear factor-κB kinase (IKK), which phosphorylates and degrades inhibitor of 
nuclear factor-κB (IκB), leading to the nuclear translocation of nuclear factor-κB (NF-κB) 
[52]. In addition, the IRE1-TRAF2 complex can also recruit the kinase Jun N-terminal Kinase 
(JNK), which can phosphorylate the transcription factor activator protein 1 (AP-1), a known 
inducer of inflammatory gene expression [53].  
A major role for the UPR in the inflammatory response is now undisputed. The active 
spliced form of XBP-1, a key regulator of chaperone and ERAD genes, has been shown to 
control the production of interleukin (IL)-6 in the mouse B cell [54]. Furthermore, XBP-1 was 
shown to direct the production of interferon (IFN)-β in mouse macrophages subjected to ER 
stress [55], while both ATF6 and XBP-1 were found to control IL-6, IL-8 and monocyte 
chemotactic protein (MCP)-1 expression in human aortic endothelial cells [56]. Interestingly, 
another group demonstrated that accumulation of free cholesterol in macrophages from a 
mouse model of atherosclerosis induced ER stress and caused the secretion of TNF-α and 
IL-6 [57, 58], highlighting a mode of cytokine production induced by intracellular events, as 
opposed to exogenous stimuli.  
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However, there is a further level of complexity. Several reports have indicated that 
inflammatory cytokines can cause ER stress and activate the UPR. TNF-α has been shown 
to activate PERK, IRE1, and ATF6 in fibrosarcoma cells [59], while Tumour necrosis factor 
(TNF)-α, IL-1β, and IL-6 induced ER stress in hepatocytes, upregulating Grp78 and spliced 
XBP-1 [60]. This cytokine-induced UPR engagement in hepatocytes led to the activation of 
the transcription factor CREBH in the Golgi by a sequential cleavage mechanism similar to 
ATF6 activation, and active CREBH then mediates the acute phase response of 
inflammatory genes such as C-reactive protein (CRP). Furthermore, a recent study in C. 
elegans demonstrated XBP-1 is activated by Pseudomonas challenge, not to neutralise the 
invading pathogen, but to protect the host from the potentially lethal ER stress caused by 
mounting a massive, secretory immune response [61].  
 
Z AAT AND THE UPR 
It has been shown that all three arms of the UPR can be activated in response to 
over-expression of ZAAT in Chinese hamster ovary (CHO), human embryonic kidney (HEK) 
293, liver HepG2 and human bronchial epithelial 16HBE14o- cell lines in vitro [7, 62-64] and 
basally in human peripheral blood monocytes isolated from ZZ individuals [6]. However, 
there is an absence of UPR activation in inducible models of ZAAT deficiency liver disease 
and in liver cells in vivo. Several studies have failed to discover UPR activation in cell culture 
and animal liver models of ZAAT deficiency [65, 66]. This has led to the hypothesis that an 
absence of UPR engagement allows the survival of cells with high intracellular levels of 
ZAAT, for example globule-containing hepatocytes.  
Recently it has emerged that ZAAT expression is also associated with abnormal 
immune cell function [6]. Peripheral blood monocytes express AAT and Carroll et al. showed 
evidence of UPR activation in vivo in monocytes from ZZ individuals and linked this 
phenomenon to an exaggerated immune response. Monocytes isolated from healthy ZZ 
individuals were hyper-responsive when stimulated with Pseudomonas lipopolysaccharide 
(LPS), and the expression of ATF4, XBP-1 and a subset of genes involved in the UPR were 
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all increased compared to MM individuals. Furthermore, increased cytokine production and 
the same UPR genes could be induced in MM monocytes by treatment with the ER stress 
inducer thapsigargin, linking the observed ZZ monocyte changes to ER stress. Confocal 
microscopy demonstrated Z AAT is retained in the ER of ZZ monocytes but that Grp78 is 
also increased even in resting cells. These altered gene expression patterns contribute to 
enhanced basal and agonist-induced cytokine production by ZZ monocytes and activation of 
the NF-κB pathway.  
These findings broaden our current understanding of the mechanisms underlying the 
lung and liver disease associated with ZAAT deficiency and shed light on the emerging 
systemic gain of function effect of the Z mutation. The traditional protease/antiprotease 
paradigm for the lung disease associated with AAT deficiency has to evolve to 
accommodate the inflammatory gain of function from accumulated ZAAT protein, including 
neutrophil chemoattraction, ER stress and concomitant inflammation.  
Several groups have confirmed that the inflammatory mediators LPS, IL-6, IL-1β, 
oncostatin-M (OSM), neutrophil elastase (NE), and TNF-α can upregulate AAT production in 
monocytes, macrophages and alveolar epithelial cells [67-71]. This is an important 
mechanism of locally regulating proteolytic activity. However, if inflammatory stimuli 
upregulate this local AAT production from alveolar macrophages and epithelial cells in the 
lungs of AAT deficient individuals, the subsequent increase in ZAAT production could cause 
activation of the UPR. Therefore, in cells producing polymerogenic ZAAT, cytokine 
production induced by the UPR could represent a self-perpetuating cycle of enhanced 
inflammatory gene expression and immune cell recruitment.  
 
Removal of misfolded ZAAT from the ER 
At least two pathways exist for the degradation of ZAAT that accumulates in the ER, 
these are known as the ER-associated degradation (ERAD) and autophagic pathways. The 
current consensus purports that soluble ZAAT is degraded in the cytosol by the proteosome 
via ERAD, whilst polymerized ZAAT is degraded by autophagy [72].  
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(i) ER associated degradation (ERAD). This is the process by which the production of mutant 
glycosylated secretory proteins are monitored, detected and diverted to the ubiquitin-
proteosome system for degradation [73, 74]. Most ERAD components exist at the ER 
membrane however the proteosome reside in the cytosol, therefore ERAD substrates are 
required to undergo retrograde transport into the cytosol for proteolysis. In order to prevent 
congestion in the ER with terminally misfolded proteins, those that cannot be refolded are 
extracted from calnexin and calreticulin. ER degradation-enhancing alpha-mannosidase-like 
(EDEM) proteins and ER mannosidase I (ERManI) regulate this process. In the context of 
ZAAT folding in the ER, the ER luminal and transmembrane proteins EDEM1, EDEM2 and 
EDEM 3 can extract misfolded ZAAT from ER chaperones and enable enzymatic trimming of 
mannose from its carbohydrate side-chain by ERManI [72]. It is likely that ZAAT is then 
‘retro-translocated’ or ‘dislocated’ to the cytosol, possibly via Sec61, Derlin and p97/Valosin-
containing Protein (VCP), modified with polyubiquitin and ultimately degraded by the 
proteosome [74]. In addition to ERAD, ZAAT can also be degraded by autophagy, a cellular 
mechanism for the degradation of cytoplasmic constituents within lysosomes.  
 
(ii) Autophagy. The macroautophagic process (herein referred to as autophagy) is the 
cellular process managing the disposal and recycling of excess or defective organelles and 
cytoplasmic and membrane constituents [75-77]. It involves de novo vesicle formation. 
Initially a flat membrane cistern – most likely derived from the ER membrane - termed the 
isolation membrane or phagophore, elongates and wraps itself around a misfolded protein or 
organelle that is destined for disposal. These components then become enveloped in a 
double-membraned vesicle termed the ‘autophagosome’. The outer membrane of this 
vesicle fuses with a lysosome to generate an ‘autophagolysosome’ which contain lysosomal 
membrane proteins and proton pumps. The generation of an autophagolysosme facilitates 
access of hydrolytic enzymes to the inner content of the vesicle and it is within these 
vesicles that constituent misfolded or long-lived proteins and excess or aberrant organelles 
(e.g. peroxisomes and mitochondria) are catabolised by resident acidic hydrolases. The 
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degradation products are transported back to the cytoplasm where they are reused for 
energy and biosynthesis of new molecules and organelles. 
Autophagy is crucial for diverse physiological processes including starvation 
responses, lipid metabolism, erythropoiesis and immune function. It is a key modulator of 
diseases characterised by aggregrate-prone proteins and has been much studied in 
neurological conformational disorders. In addition to being a nutrient starvation and 
misfolded protein response, autophagy has now also been implicated in the processes of 
infection, repair and apoptosis and a variety of cellular stresses are known to induce 
autophagy including viral infection or the UPR [75, 77, 78]. Much of what we know regarding 
autophagy has been gleaned from studies in yeast. This work has demonstrated a key role 
for autophagy-related gene (ATG) 6 (called Beclin-1 in mammals) in autophagy. It can 
interact with a complex of proteins including the phophoinositol-3-kinase vesicle-mediated 
vacuolar sorting protein (Vsp) 34 and Ambra 1 to promote Vsp15, UV-irradiation resistance-
associated gene (UVRAG) and BAX-interacting factor-1(Bif-1)-mediated autophagy [79-83]. 
Autophagy is also an important mechanism involved in ZAAT deficiency. There are 
three autophagy gene products ATG5, ATG6 and ATG16 that are particularly important for 
the autophagic digestion of aggregated ZAAT [84]. Expansion and dilatation of the ER and 
increased numbers of autophagosomes, two morphological changes characteristic of 
autophagy, are evident in fibroblasts overexpressing ZAAT, in ZAAT mouse liver cells and 
liver cells from ZAAT individuals [85-88]. In addition to macroautophagy, other autophagic 
processes exist including microautophagy and chaperone-mediated autophagy, each with 
specific functions. Another form of autophagy that involves removal of damaged or 
exhausted mitochondria is termed ‘mitophagy’ [89]. In ZAAT deficiency mitophagy is likely to 
be an important process in the liver given that mitochondrial dysfunction has been observed 
in patient liver samples and mouse models [88]. 
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ER Overload response (EOR)  
The proinflammatory transcription factor NF-κB can be activated by a range of 
diverse stimuli including UV light, microbial infection or proinflammatory cytokines. 
Classically these agonists engage cell surface receptors and initiate intracellular signal 
transduction pathways converging at IKK, an enzyme complex composed of IKKα,-β and -γ 
subunits. Importantly however for individuals with ZAAT deficiency, IKK can also be 
activated in response to accumulation of misfolded proteins in the ER. The IKK complex 
phosphorylates the NF-κB inhibitory proteins IκB-α, -β and -γ on key serine residues, leading 
to their tagging with ubiquitin and ultimate recognition and degradation by the proteosome. 
Following removal of IκB proteins from NF-κB dimers, nuclear localisation sequences are 
exposed on NF-κB freeing it to translocate to the nucleus where it can binds to NF-κB 
recognition elements in the promoter of target genes and promote their transcription.  
 
ZAAT AND THE EOR 
We and others have investigated NF-κB activation in the context of ER accumulation 
of misfolded ZAAT in a variety of cell types including CHO cells, human bronchial epithelial 
cells (16HBE14o-), liver cell lines and animal and human biopsies, and also in human 
peripheral blood monocytes [7, 62]. In all cell types studied expression of ZAAT is 
associated with activation of NF-κB. Electrophoretic mobility shift assays of nuclear extracts 
from CHO cells transfected with an empty vector, normal M or mutant Z AAT cDNAs showed 
that expression of ZAAT enhances NF-κB nuclear localisation and ability to bind to DNA 
compared to control cells. We also performed studies overexpressing wild type or mutant 
AAT transgenes in 16HBE14o- human bronchial epithelial cells and found significantly 
increased IL-8 and IL-6 production in ZAAT-expressing cells. IL-6 and IL-8 are 
proinflammatory cytokines; their expression is positively regulated by NF-κB. This study 
provided the first evidence that misfolded ZAAT is associated with a gain of function that 
may have the potential to impact on the lung disease associated with AAT deficiency.  
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In liver cells in cell culture, in animal models of ZAAT deficiency and also in vivo in 
liver biopsies from ZZ homozygous individuals NF-κB activation has been detected [64, 65]. 
In liver cells it is possible that activation of NF-κB in response to accumulation of ZAAT may 
mediate inflammation and neutrophil infiltration via up regulation of IL-8. Given that NF-κB is 
involved in inflammation-associated carcinogenesis, EOR may have a role in the 
pathogenesis of hepatocellular carcinoma in ZAAT-deficient individuals [90].  
Whilst UPR and EOR are often depicted as discrete signals activated during the ER 
stress response it now becoming evident that UPR signalling can directly impact on and 
regulate proinflammatory gene expression (Figure 2). Indeed various forms of cross-talk 
between different ER stress-induced pathways can occur.  
 
 
ER stress-induced apoptosis 
Although NF-κB is largely cytoprotective, when the stress induced by the presence of 
a misfolded protein in the ER is prolonged cell death may occur via apoptosis. ER stress-
induced apoptosis can occur by a number of different mechanisms. The best characterised 
pathways involve key UPR proteins and other ER membrane-resident factors (Figure 3) [91].  
(i) PERK-CHOP-GADD34. Activation of PERK can promote cell survival by inducing the 
expression of specific UPR survival genes, however under conditions of prolonged ER 
stress, PERK-mediated activation of ATF4 leads to the expression of CHOP [92] (also called 
GADD153) and the pro-apoptotic genes NOXA and Bim [91, 93]. Cell cycle arrest occurs 
following CHOP overexpression due to enhanced expression of the pro-apoptotic genes 
Tribbles homologue 3 (TRB3), death receptor 5 (DR5) and carbonic anhydrase IV (CAVI) 
[94-96]. CHOP also promotes apoptosis by activating the ER oxidase ERO1α which 
dimerises with cAMP-responsive element binding protein (CREB) and suppresses 
expression of the anti-apoptotic protein Bcl2 [97, 98]. A further apoptotic strategy facilitated 
by CHOP includes the upregulation of GADD34. 
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(ii) IRE1-TRAF2-JNK. Following its activation IRE1α not only splices XPB-1 leading to the 
transcriptional induction of CHOP, but also interacts with TRAF2 and apoptosis signal 
regulating kinase 1 (ASK1) initiating a signalling cascade leading to activation of the 
mitogen-activated protein kinase JNK [99-102]. Phosphorylation of Bcl2 and Bim 
concomitantly inhibits and activates these two proteins, respectively, further promoting 
apoptosis [53]. 
(iii) Bax/Bak-calpain-caspases. Although not directly related to UPR signalling the third 
apoptotic pathway induced by ER stress does also emanate from the ER membrane. In 
response to ER stress the pro-apoptotic proteins Bak and Bax can undergo a conformational 
change enabling Ca2+ efflux from the ER into the cytoplasm [103]. This event leads to 
activation of the Ca2+-dependent cysteine protease calpain which can cleave caspase-12 
[104]. In turn procaspase-9 is cleaved, activated and forms an apoptosome with cytochrome 
c (also released from mitochondria by the cytoplasmic Ca2+ influx) and apoptotic protease 
activating factor 1 (Apaf-1). Finally the executioner caspase, caspase-3, becomes activated. 
As caspase-12 is not expressed in humans, caspase-4 has been proposed to represent the 
functional homologue of murine caspase-12, however its exact role in ER stress-induced 
apoptosis remains unclear. 
 
ZAAT AND ER STRESS-INDUCED APOPTOSIS 
We have evaluated the effect of ER accumulation of ZAAT on apoptosis in HEK293 
cells using the ER stress agonist thapsigargin and MAAT and ZAAT transgenes [63]. We 
found that, similar to treatment with thapsigargin, expression of ZAAT, but not MAAT, 
induced cleavage of procaspase-4 and downstream executioner caspases. Given the poorly 
defined role of caspase-4 in ER stress-induced apoptosis which tends to be stimulus and cell 
type specific we decided to investigate its role in ZAAT-induced cell death. To evaluate this 
we knocked-down caspase-4 protein expression in HEK293 cells. Interestingly this did not 
promote cell survival in ZAAT expressing cells, nor did it inhibit ZAAT-induced caspase-7 
activation. These data led us to conclude that caspase-4 is not at the apex of the ZAAT/ER-
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induced apoptotic signalling pathway and is not essential for ER-mediated apoptosis in 
HEK293 cells.  
Next we used the bile acid tauroursodeoxycholic acid (TUDCA) to further investigate 
the mechanism of ZAAT-induced apoptosis. We focussed on the effect of TUDCA on the 
pro-apoptotic Bcl family member Bad, an inhibitor of Bcl2. TUDCA treatment of ZAAT-
expressing HEK293 cells led to phosphorylation and inactivation of Bad, an event that can 
release and activate Bcl2 and promote cell survival. These studies suggest that ZAAT-
induced apoptosis in HEK293 cells is likely to involve Bad-mediated inhibition of Bcl2 and 
supports other models that describe Bcl2 as an important inhibitory target during ER stress-
induced apoptosis 
We performed similar studies in airway epithelial cells. When we assayed 
16HBE14o- cells expressing ZAAT for indices of ER stress-induced apoptosis we found that 
ZAAT had no apparent affect on apoptosis, notwithstanding its ability to activate other ER 
stress cascades [7]. Surprisingly we actually observed an inhibition of basal caspase-3 
activity in 16HBE14o- cells expressing either MAAT or ZAAT. Concurrently it was reported 
that MAAT can directly inhibit caspase-3 activity and apoptosis in lung endothelial cells via 
inhibition of caspase-3 substrate binding [105]. 
In order to address the apparent dichotomy regarding the pro- and anti-apoptotic 
effects of ZAAT when expressed in HEK293 versus 16HBE14o- cells we investigated the 
effects of ZAAT on the expression of a range of pro- and anti-apoptotic genes in both cell 
types. Our experiments showed no involvement of Bax, cellular inhibitor of apoptosis (cIAP) 
2 or x-linked inhibitor of apoptosis protein (XIAP), nor did we see a down regulation of the 
expression of a range of pro-apoptotic factors by ZAAT. We did however observe an 
increase in the expression of cIAP1 in 16HBE14o- cells expressing ZAAT and also detected 
increased expression of cIAP1 in ZAAT-expressing bronchial epithelial cells in vivo. cIAP1 is 
a member of the inhibitor of apoptosis family that enhances cell survival in response to 
diverse stimuli [106, 107]. It also acts as an upstream regulator of NF-κB [108]. Interestingly 
expression of ZAAT failed to induce cIAP1 expression in the HEK293 cells, providing an 
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explanation for the different apoptotic responses displayed by both cell lines in response to 
over expression of ZAAT. 
 Using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
staining we could detect terminal apoptosis in HEK293 cells expressing ZAAT [63]. However 
in contrast to these in vitro studies, increased apoptosis has not been detected histologically 
or by TUNEL staining in the livers of ZAAT mice. One possible explanation for this may be 
the robust regenerative and cell survival properties of hepatocytes. Alternatively it may be a 
consequence of the highly specific stimulus- and cell type-specific nature of ER stress 
responses. The mechanism by which the caspase pathway is inhibited in ZAAT-containing 
hepatocytes remains unknown but could possibly be related to MAAT and ZAAT’s known 
anti-apoptotic effects [7, 105]. However, the mechanism by which ZAAT might gain access 
to caspase-3 in the cytosol of liver cells is not known.  
In summary expression of ZAAT can induce apoptosis mediated via inhibition of Bcl2 
in HEK293 cells however, to date, ZAAT expression in vivo in hepatocytes or bronchial 
epithelial cells does not appear to have the same effect. It remains to be demonstrated 
whether endogenous expression of ZAAT in human monocytes or alveolar macrophages 
promotes cell death. Taken together these data imply that ZAAT-induced apoptosis or 
survival is an inherent feature of the cell in which ZAAT is expressed.  
 
Conclusion 
In ZAAT deficiency the misfolded protein results in both loss of function and gain. In 
addition to the chemotactic and proinflammatory properties of misfolded ZAAT, its 
accumulation in the ER has the potential to induce multiple signalling events related to ER 
stress. With respect to this toxic gain it is now emerging that these effects are not limited 
solely to hepatocytes, as previously thought. Interestingly, although perturbation of the ER 
can be induced by ZAAT expression in most cells, important differences exists in the 
responses induced in different cell types. The next steps in enhancing our understanding of 
these mechanisms will be to identify these stimulus- and cell-specific responses. Over the 
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past few years research has increased our awareness of the effects of misfolded ZAAT not 
only in the liver but throughout the body and particularly in the lung. This has importance for 
future therapies aimed at ZAAT deficiency. New treatments for both the liver disease and the 
chronic inflammation in the lungs are likely to be aimed at suppressing the pro-inflammatory 
effects of misfolded proteins and selectively modulating ER stress responses to enhance 
folding and/or disposal. Harnessing control of individual pathways may become possible by 
specifically targeting key ER stress proteins positioned at the apex of signalling cascades. 
For example promoting autophagy [109, 110] or ERAD could decrease the load of misfolded 
ZAAT within the ER and enhance cellular function. This knowledge we will advance our 
progress in the development of specific therapeutics for ZAAT deficient individuals. 
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Figure 1. Conceptual schematic of the unfolded protein response. 
Accumulation of a misfolded protein e.g. ZAAT in the ER lumen titrates Bip/Grp78 away from 
PERK, ATF6 and IRE1 leading to their activation. PERK dimerises, becomes 
phosphorylated and inactivates eIF2α - this blocks translation via eIF2B. ATF4 gene and 
protein expression are induced leading to ATF4-regulated gene expression, including 
GADD34 which stimulates protein phophatase-1 (PP1) and triggers dephosphorylation of 
eIF2α. Nrf2 is activated by PERK, translocates to the nucleus and induces antioxidant gene 
expression. The transcription factor ATF6 is transported to the Golgi and cleaved by the 
proteases S1P and S2P to generate the active ATF6p50 which upregulates expression of 
XBP1 and chaperone genes. IRE1 becomes phosphorylated, assembles into multimers and 
splices XBP1 (uXBP1) to generate XBP1s mRNA which encodes a transcription factor that 
regulates expression of EDEM1 and chaperones.  
 
Figure 2. Potential cross-talk between different ER stress pathways. 
UPR can induce and inhibit apoptosis via CHOP and ATF4, respectively, whilst EOR has a 
largely negative effect on apoptosis by the activation of NFκB. UPR can activate NFκB/EOR 
and promote proinflammatory cytokine expression, with these in turn leading to further UPR 
activation.  
 
Figure 3. Pathways of ER stress-induced apoptosis. 
PERK-mediated activation of ATF4 leads to the expression of pro-apoptotic CHOP, NOXA 
and Bim. CHOP also enhances expression of DR5, TRB3, CAVI and GADD34 and activates 
ERO1α leading to suppression of Bcl2. IRE1α splices XPB-1 leading to upregulation of 
CHOP expression. IRE1α signals via TRAF2 and ASK1 to activate JNK which then 
phosphorylates of Bcl2 and Bim. The proapoptotic proteins Bak and Bax undergo a 
conformational change, Ca2+ effluxes from the ER and activates calpain which cleave 
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caspase-12 (or possibly caspase-4). Signalling via caspase-9 cytochrome c and Apaf-1 
activates caspase-3.  
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